Efficacy of anti-influenza immunoglobulin (FLU-IGIV) in ferrets and mice infected with 2009 pandemic influenza virus

Antiviral Res. 2020 Aug:180:104753. doi: 10.1016/j.antiviral.2020.104753. Epub 2020 Feb 27.

Abstract

Seasonal influenza causes significant morbidity and mortality around the world each year, even with the use of vaccines and antivirals. There is a need for more effective treatments for severe and hospitalized cases of influenza. In this study, we have tested the efficacy of a human plasma-derived IgG product (FLU-IGIV) against seasonal influenza in mouse and ferret models of influenza infection. FLU-IGIV successfully protected mice (100% survival) against lethal influenza infection. Also, the survival rate observed with FLU-IGIV treatment was better than the survival rate observed with oseltamivir (60% survival). FLU-IGIV significantly reduced the viral load in the lungs compared to placebo (PBS) in ferrets infected with influenza A/California/07/2009 (H1N1pdm09) virus. Overall, these studies demonstrate the efficacy of human plasma-derived FLU-IGIV in relevant animal models of influenza virus infection.

Keywords: Efficacy; FLU-IGIV; H1N1pdm09; Pharmacokinetics; Seasonal influenza.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral / therapeutic use*
  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / therapeutic use*
  • Dose-Response Relationship, Immunologic
  • Female
  • Ferrets / virology
  • Humans
  • Immunoglobulins, Intravenous / pharmacokinetics
  • Immunoglobulins, Intravenous / therapeutic use*
  • Influenza A Virus, H1N1 Subtype
  • Mice
  • Mice, Inbred BALB C
  • Orthomyxoviridae Infections / therapy*
  • Pandemics
  • Viral Load / drug effects

Substances

  • Antibodies, Viral
  • Antiviral Agents
  • Immunoglobulins, Intravenous